Jeroen Dekervel
@JDekervel
MD - GI oncology @uzleuven @KU_Leuven
🎙️ New #ESMO Podcast – Controversies in Upper GI Cancers 📌 Radiotherapy in borderline resectable #PDAC: Evidence vs practice – when does it make sense? @NiuSanford & @BasGrootKoerkam join me to discuss a case & key trials. 🎧 Listen: open.spotify.com/episode/6NFOKd… #PancreaticCancer
That was a great discussion led by @JDekervel . Thanks to @myESMO for the invitation!
🎧 Another @myESMO Upper GI podcast! We break down key #ASCO25 updates in #EsophagealCancer & #GastricCancer: ✔️ CheckMate 577 ✔️ Matterhorn ✔️ DESTINY-Gastric04 ✔️ SATRi-cel (CAR-T!) With @LizzySmyth1, Sylvie Lorenzen & @ThAlcin 🎙 Listen now: open.spotify.com/episode/65JSJu… #GIonc
🎧 Another @myESMO Upper GI podcast! We break down key #ASCO25 updates in #EsophagealCancer & #GastricCancer: ✔️ CheckMate 577 ✔️ Matterhorn ✔️ DESTINY-Gastric04 ✔️ SATRi-cel (CAR-T!) With @LizzySmyth1, Sylvie Lorenzen & @ThAlcin 🎙 Listen now: open.spotify.com/episode/65JSJu… #GIonc
🎧 New @myESMO upper GI podcast! We unpack key #ASCO25 updates in #PancreaticCancer & #BiliaryCancer: ✔️ CASSANDRA ✔️ PANOVA-3 ✔️ Elraglusib ✔️ GAIN & POLCA-GB w/ @ArndtVogel & Florian Castet 🎙 Listen: open.spotify.com/episode/47uQnC… #GIonc
🥁 Another fantastic @myESMO GI oncology podcast about #oligometastatic #gastric cancer is finally out! @HannekevanLaar1 @tfleitask Please take a moment to 🎧 and share it with your team: soundcloud.com/esmo-podcasts/…
🎥 #ASCO2025 In-Depth! Prof Eric Van Cutsem & Prof @JDekervel Dekervel on DESTINY-Gastric04: ✔️ T-DXd OS +3.3 mo vs 2L SOC ✔️ ORR 44%, ILD 13% (mostly mild) ✔️ EMA: rebiopsy not required 👀 Watch now bit.ly/4mLvOXR #MediMix #HER2 #GastricCancer #TDXd
💡GI Highlight from #ASCO2025! Prof @JDekervel shares updates on 3 promising trials in pancreatic cancer: ✔️ PAXG > FOLFIRINOX in EFS (CASSANDRA) ✔️ TTF: modest OS benefit in locally advanced disease ✔️ Elraglusib: GSK-3β inhibitor adds 3 months OS
💡GI Highlight from #ASCO2025! Prof @JDekervel shares key findings in GI oncology: 🧪 Nivolumab OS trend (CHECKMATE 577) 🧪 PFS benefit in LEAP-015 🧪 Early signals from GAIN in BTC 🎥 Watch now bit.ly/4mLvOXR #MediMix #Oncology #GICancer
🔥 #ASCO2025 Plenary GI In-depth! Prof Van Cutsem & Prof @JDekervel on the MATTERHORN trial: ✅ Durvalumab + FLOT = improved EFS ✅ Better tumour control, no extra toxicity ✅ Promising new standard for gastric cancer 🎥 Watch now bit.ly/4mLvOXR #MediMix #GastricCancer…
Absolutely stunning!! This is the very role of academic clinical research. Should be explored in other cancer types as well.
What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72…
Cannot stress enough this is a huge opportunity and a great experience @myESMO
ESMO Leadership Programme 2025-2026: Applications are open! This is a unique opportunity to enhance your #LeadershipSkills while broadening perspectives, and building lasting connections. 📅 Apply by 15 June 2025, 00:00 CEST 🔗 ow.ly/S4eT50VVtlQ
#LCSM @asco PROVE ME WRONG! Early vs Late Time-of-Day (3PM cutoff) ICI dosing in 1st-line stage IIIC-IV NSCLC: randomized trial shows near doubling of PFS (13.2 vs 6.5 mo), better OS & ORR with morning infusions. Circadian rhythm matters? Will practice change? This is the…
#ASCO25 DYNAMIC-III coming in with the most surprising result of the year! ctDNA adapted RCT of stage III resected colon cancer (escalation of therapy) ~ 1000 patients, 259 with ctDNA+ disease, randomized 1:1 to SOC vs escalation If ctDNA +: 5-FU -> FOLFOX FOLFOX ->…
🔬 Targeted therapy in focus! Explore IDH1-mutant cholangiocarcinoma management in our new video with Prof @JDekervel , Prof Demols and Prof Geboes.
Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…
#SAFIR-#ABC10, an important #ClinicalTrial in #Biliary recruiting in UK, France and Belgium (not Spain 😔) #Randomsied phase III Allows molecular profiling + discussion at a #MolecTumorBoard Explores #maintenance #targeted after Chemo+IO (x4cycles) HUGE effort - Congrats 👏🏻👏🏻
Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper @ESMO_Open! authors.elsevier.com/sd/article/S20…
Patients with ATM, CHEK2, or PALB2 pathogenic variants had similar breast, colorectal, and pancreatic cancer mortality to the average genetically tested patient with their cancer type. ascopubs.org/doi/abs/10.120…
‼️Our latest publication in @JHepatology ‼️ ✅Response to atezo+bev in HCC is immune- vs angiogenesis-driven. ⛔️Resistance is associated with immunosuppressive myeloid cells and Notch activation. 👉Molecular subgroups define distinct clinical outcomes. journal-of-hepatology.eu/article/S0168-…
I recently had a chat with @JDekervel about one of our favourite topics… Biomarkers in HCC: why we need them, and why they are so difficult to identify.. Have a listen!! 🎧 🎙️👇
🎙️ New podcast episode: Biomarkers in #HCC 🔬 Join Sarah Cappuyns (Y-ILCA) and Jeroen Dekervel (Digestive Oncologist, Leuven) as they dive into the role of biomarkers in #HCC treatment. 🎧 Listen now: open.spotify.com/episode/4bc3OD…
🎙️ Podcast on biomarkers in #HCC - @CappuynsSarah 🔥
🎙️ New podcast episode: Biomarkers in #HCC 🔬 Join Sarah Cappuyns (Y-ILCA) and Jeroen Dekervel (Digestive Oncologist, Leuven) as they dive into the role of biomarkers in #HCC treatment. 🎧 Listen now: open.spotify.com/episode/4bc3OD…